Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 119

1.

Long-term safety of certolizumab pegol in rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis, psoriasis and Crohn's disease: a pooled analysis of 11 317 patients across clinical trials.

Curtis JR, Mariette X, Gaujoux-Viala C, Blauvelt A, Kvien TK, Sandborn WJ, Winthrop K, de Longueville M, Huybrechts I, Bykerk VP.

RMD Open. 2019 May 31;5(1):e000942. doi: 10.1136/rmdopen-2019-000942. eCollection 2019.

2.

Treatment strategies in early rheumatoid arthritis methotrexate management: Results from a prospective cohort.

Moura CS, Schieir O, Valois MF, Thorne C, Bartlett SJ, Pope JE, Hitchon CA, Boire G, Haraoui B, Hazlewood GS, Keystone EC, Tin D, Bykerk VP, Bernatsky S; Canadian Early Arthritis Cohort (CATCH) Investigators.

Arthritis Care Res (Hoboken). 2019 May 21. doi: 10.1002/acr.23927. [Epub ahead of print]

PMID:
31112011
3.

HBEGF+ macrophages in rheumatoid arthritis induce fibroblast invasiveness.

Kuo D, Ding J, Cohn IS, Zhang F, Wei K, Rao DA, Rozo C, Sokhi UK, Shanaj S, Oliver DJ, Echeverria AP, DiCarlo EF, Brenner MB, Bykerk VP, Goodman SM, Raychaudhuri S, Rätsch G, Ivashkiv LB, Donlin LT.

Sci Transl Med. 2019 May 8;11(491). pii: eaau8587. doi: 10.1126/scitranslmed.aau8587.

4.

Defining inflammatory cell states in rheumatoid arthritis joint synovial tissues by integrating single-cell transcriptomics and mass cytometry.

Zhang F, Wei K, Slowikowski K, Fonseka CY, Rao DA, Kelly S, Goodman SM, Tabechian D, Hughes LB, Salomon-Escoto K, Watts GFM, Jonsson AH, Rangel-Moreno J, Meednu N, Rozo C, Apruzzese W, Eisenhaure TM, Lieb DJ, Boyle DL, Mandelin AM 2nd; Accelerating Medicines Partnership Rheumatoid Arthritis and Systemic Lupus Erythematosus (AMP RA/SLE) Consortium, Boyce BF, DiCarlo E, Gravallese EM, Gregersen PK, Moreland L, Firestein GS, Hacohen N, Nusbaum C, Lederer JA, Perlman H, Pitzalis C, Filer A, Holers VM, Bykerk VP, Donlin LT, Anolik JH, Brenner MB, Raychaudhuri S.

Nat Immunol. 2019 Jul;20(7):928-942. doi: 10.1038/s41590-019-0378-1. Epub 2019 May 6.

PMID:
31061532
5.

Long-term safety and effectiveness of tocilizumab in patients with rheumatoid arthritis and inadequate responses to csDMARDs and/or TNF inhibitors: an open-label study close to clinical practice.

Bykerk VP, Östör AJK, Alvaro-Gracia J, Pavelka K, Román Ivorra JA, Nurmohamed MT, Luder Y, Sidiropoulos PNM, Devenport J, Sibilia J.

Clin Rheumatol. 2019 Sep;38(9):2411-2421. doi: 10.1007/s10067-019-04535-z. Epub 2019 Apr 26.

PMID:
31028551
6.

Re-treatment with abatacept plus methotrexate for disease flare after complete treatment withdrawal in patients with early rheumatoid arthritis: 2-year results from the AVERT study.

Emery P, Burmester GR, Bykerk VP, Combe BG, Furst DE, Maldonado MA, Huizinga TW.

RMD Open. 2019 Feb 8;5(1):e000840. doi: 10.1136/rmdopen-2018-000840. eCollection 2019.

7.

Patient-Reported Outcomes Measurement Information System Versus Legacy Instruments: Are They Ready for Prime Time?

Bykerk VP.

Rheum Dis Clin North Am. 2019 May;45(2):211-229. doi: 10.1016/j.rdc.2019.01.006. Review.

PMID:
30952394
8.

Low-dose Glucocorticoid Use Does Not Reduce Biologic Use in Early RA, Nor Do Biologics Reduce the Need for Glucocorticoids.

Bykerk VP.

J Rheumatol. 2019 Apr;46(4):331-332. doi: 10.3899/jrheum.181262. No abstract available.

PMID:
30936221
9.

Histologic and Transcriptional Evidence of Subclinical Synovial Inflammation in Patients With Rheumatoid Arthritis in Clinical Remission.

Orange DE, Agius P, DiCarlo EF, Mirza SZ, Pannellini T, Szymonifka J, Jiang CS, Figgie MP, Frank MO, Robinson WH, Donlin LT, Rozo C, Gravallese EM, Bykerk VP, Goodman SM.

Arthritis Rheumatol. 2019 Jul;71(7):1034-1041. doi: 10.1002/art.40878. Epub 2019 Jun 5.

PMID:
30835943
10.

PROMIS Fatigue short forms are reliable and valid in adults with rheumatoid arthritis.

Bingham Iii CO, Gutierrez AK, Butanis A, Bykerk VP, Curtis JR, Leong A, Lyddiatt A, Nowell WB, Orbai AM, Bartlett SJ.

J Patient Rep Outcomes. 2019 Feb 21;3(1):14. doi: 10.1186/s41687-019-0105-6.

11.

Patient Perspectives on DMARD Safety Concerns in Rheumatology Trials: Results from Inflammatory Arthritis Patient Focus Groups and OMERACT Attendees Discussion.

Andersen KM, Kelly A, Lyddiatt A, Bingham CO 3rd, Bykerk VP, Batterman A, Westreich J, Jones MK, Cross M, Brooks PM, March L, Shea B, Tugwell P, Simon LS, Christensen R, Bartlett SJ.

J Rheumatol. 2019 Sep;46(9):1168-1172. doi: 10.3899/jrheum.181185. Epub 2019 Feb 15.

PMID:
30770516
12.

Correction to: On-drug and drug-free remission by baseline symptom duration: abatacept with methotrexate in patients with early rheumatoid arthritis.

Bykerk VP, Burmester GR, Combe BG, Furst DE, Huizinga TWJ, Ahmad HA, Emery P.

Rheumatol Int. 2019 May;39(5):945. doi: 10.1007/s00296-018-4232-9.

13.

On-drug and drug-free remission by baseline symptom duration: abatacept with methotrexate in patients with early rheumatoid arthritis.

Bykerk VP, Burmester GR, Combe BG, Furst DE, Huizinga TWJ, Ahmad HA, Emery P.

Rheumatol Int. 2018 Dec;38(12):2225-2231. doi: 10.1007/s00296-018-4173-3. Epub 2018 Oct 20. Erratum in: Rheumatol Int. 2019 Feb 5;:.

14.

Mixed-effects association of single cells identifies an expanded effector CD4+ T cell subset in rheumatoid arthritis.

Fonseka CY, Rao DA, Teslovich NC, Korsunsky I, Hannes SK, Slowikowski K, Gurish MF, Donlin LT, Lederer JA, Weinblatt ME, Massarotti EM, Coblyn JS, Helfgott SM, Todd DJ, Bykerk VP, Karlson EW, Ermann J, Lee YC, Brenner MB, Raychaudhuri S.

Sci Transl Med. 2018 Oct 17;10(463). pii: eaaq0305. doi: 10.1126/scitranslmed.aaq0305.

15.

Methods for high-dimensonal analysis of cells dissociated from cyropreserved synovial tissue.

Donlin LT, Rao DA, Wei K, Slowikowski K, McGeachy MJ, Turner JD, Meednu N, Mizoguchi F, Gutierrez-Arcelus M, Lieb DJ, Keegan J, Muskat K, Hillman J, Rozo C, Ricker E, Eisenhaure TM, Li S, Browne EP, Chicoine A, Sutherby D, Noma A; Accelerating Medicines Partnership RA/SLE Network, Nusbaum C, Kelly S, Pernis AB, Ivashkiv LB, Goodman SM, Robinson WH, Utz PJ, Lederer JA, Gravallese EM, Boyce BF, Hacohen N, Pitzalis C, Gregersen PK, Firestein GS, Raychaudhuri S, Moreland LW, Holers VM, Bykerk VP, Filer A, Boyle DL, Brenner MB, Anolik JH.

Arthritis Res Ther. 2018 Jul 11;20(1):139. doi: 10.1186/s13075-018-1631-y.

16.

Combining online and in-person methods to evaluate the content validity of PROMIS fatigue short forms in rheumatoid arthritis.

Bartlett SJ, Gutierrez AK, Butanis A, Bykerk VP, Curtis JR, Ginsberg S, Leong AL, Lyddiatt A, Nowell WB, Orbai AM, Smith KC, Bingham CO 3rd.

Qual Life Res. 2018 Sep;27(9):2443-2451. doi: 10.1007/s11136-018-1880-x. Epub 2018 May 24.

17.

Rheumatoid arthritis: Moving towards IMPROVED drug-free remission.

Bykerk VP.

Nat Rev Rheumatol. 2018 Mar 21;14(4):191-192. doi: 10.1038/nrrheum.2018.49. No abstract available.

PMID:
29559711
18.

Flares in Patients with Rheumatoid Arthritis after Total Hip and Total Knee Arthroplasty: Rates, Characteristics, and Risk Factors.

Goodman SM, Bykerk VP, DiCarlo E, Cummings RW, Donlin LT, Orange DE, Hoang A, Mirza S, McNamara M, Andersen K, Bartlett SJ, Szymonifka J, Figgie MP.

J Rheumatol. 2018 May;45(5):604-611. doi: 10.3899/jrheum.170366. Epub 2018 Mar 15.

PMID:
29545451
19.

Functionally distinct disease-associated fibroblast subsets in rheumatoid arthritis.

Mizoguchi F, Slowikowski K, Wei K, Marshall JL, Rao DA, Chang SK, Nguyen HN, Noss EH, Turner JD, Earp BE, Blazar PE, Wright J, Simmons BP, Donlin LT, Kalliolias GD, Goodman SM, Bykerk VP, Ivashkiv LB, Lederer JA, Hacohen N, Nigrovic PA, Filer A, Buckley CD, Raychaudhuri S, Brenner MB.

Nat Commun. 2018 Feb 23;9(1):789. doi: 10.1038/s41467-018-02892-y.

20.

Single-cell RNA-seq of rheumatoid arthritis synovial tissue using low-cost microfluidic instrumentation.

Stephenson W, Donlin LT, Butler A, Rozo C, Bracken B, Rashidfarrokhi A, Goodman SM, Ivashkiv LB, Bykerk VP, Orange DE, Darnell RB, Swerdlow HP, Satija R.

Nat Commun. 2018 Feb 23;9(1):791. doi: 10.1038/s41467-017-02659-x.

21.

Identification of Three Rheumatoid Arthritis Disease Subtypes by Machine Learning Integration of Synovial Histologic Features and RNA Sequencing Data.

Orange DE, Agius P, DiCarlo EF, Robine N, Geiger H, Szymonifka J, McNamara M, Cummings R, Andersen KM, Mirza S, Figgie M, Ivashkiv LB, Pernis AB, Jiang CS, Frank MO, Darnell RB, Lingampali N, Robinson WH, Gravallese E; Accelerating Medicines Partnership in Rheumatoid Arthritis and Lupus Network, Bykerk VP, Goodman SM, Donlin LT.

Arthritis Rheumatol. 2018 May;70(5):690-701. doi: 10.1002/art.40428. Epub 2018 Apr 2.

22.

High Adherence to System-Level Performance Measures for Rheumatoid Arthritis in a National Early Arthritis Cohort Over Eight Years.

Barber CEH, Schieir O, Lacaille D, Marshall DA, Barnabe C, Hazlewood G, Thorne JC, Ahluwalia V, Bartlett SJ, Boire G, Haraoui B, Hitchon C, Keystone E, Tin D, Pope JE, Denning L, Bykerk VP; Canadian Early Arthritis Cohort Investigators.

Arthritis Care Res (Hoboken). 2018 Jun;70(6):842-850. doi: 10.1002/acr.23439. Epub 2018 Mar 25.

23.

Corrigendum to "Klinefelter's syndrome (47,XXY) is in excess among men with Sjögren's syndrome" [Clin. Immunol. 168 (2016) 25-29].

Harris VM, Sharma R, Cavett J, Kurien BT, Liu K, Koelsch KA, Rasmussen A, Radfar L, Lewis D, Stone DU, Kaufman CE, Li S, Segal B, Wallace DJ, Weisman MH, Venuturupalli S, Kelly JA, Alarcon-Riquelme ME, Pons-Estel B, Jonsson R, Lu X, Gottenberg JE, Anaya JM, Cunninghame-Graham DS, Huang AJW, Brennan MT, Hughes P, Alevizos I, Miceli-Richard C, Keystone EC, Bykerk VP, Hirschfield G, Xie G, Siminovitch KA, Ng WF, Nordmark G, Bucher SM, Eriksson P, Omdal R, Rhodus NL, Rischmueller M, Rohrer M, Wahren-Herlenius M, Witte T, Mariette X, Lessard CJ, Harley JB, Sivils KL, Scofield RH.

Clin Immunol. 2018 Feb;187:137-138. doi: 10.1016/j.clim.2017.11.012. Epub 2017 Dec 7. No abstract available.

PMID:
29195081
24.

Overweight, Obesity, and the Likelihood of Achieving Sustained Remission in Early Rheumatoid Arthritis: Results From a Multicenter Prospective Cohort Study.

Schulman E, Bartlett SJ, Schieir O, Andersen KM, Boire G, Pope JE, Hitchon C, Jamal S, Thorne JC, Tin D, Keystone EC, Haraoui B, Goodman SM, Bykerk VP; CATCH Investigators.

Arthritis Care Res (Hoboken). 2018 Aug;70(8):1185-1191. doi: 10.1002/acr.23457. Epub 2018 Jul 13.

25.

Early Rheumatoid Arthritis Presentation, Treatment, and Outcomes in Aboriginal Patients in Canada: A Canadian Early Arthritis Cohort Study Analysis.

Nagaraj S, Barnabe C, Schieir O, Pope J, Bartlett SJ, Boire G, Keystone E, Tin D, Haraoui B, Thorne JC, Bykerk VP, Hitchon C; Canadian Early Arthritis Cohort Study Investigators.

Arthritis Care Res (Hoboken). 2018 Aug;70(8):1245-1250. doi: 10.1002/acr.23470.

26.

Content and Construct Validity, Reliability, and Responsiveness of the Rheumatoid Arthritis Flare Questionnaire: OMERACT 2016 Workshop Report.

Bartlett SJ, Barbic SP, Bykerk VP, Choy EH, Alten R, Christensen R, den Broeder A, Fautrel B, Furst DE, Guillemin F, Hewlett S, Leong AL, Lyddiatt A, March L, Montie P, Pohl C, Scholte Voshaar M, Woodworth TG, Bingham CO 3rd.

J Rheumatol. 2017 Oct;44(10):1536-1543. doi: 10.3899/jrheum.161145. Epub 2017 Aug 15.

27.

Rare X Chromosome Abnormalities in Systemic Lupus Erythematosus and Sjögren's Syndrome.

Sharma R, Harris VM, Cavett J, Kurien BT, Liu K, Koelsch KA, Fayaaz A, Chaudhari KS, Radfar L, Lewis D, Stone DU, Kaufman CE, Li S, Segal B, Wallace DJ, Weisman MH, Venuturupalli S, Kelly JA, Pons-Estel B, Jonsson R, Lu X, Gottenberg JE, Anaya JM, Cunninghame-Graham DS, Huang AJW, Brennan MT, Hughes P, Alevizos I, Miceli-Richard C, Keystone EC, Bykerk VP, Hirschfield G, Nordmark G, Bucher SM, Eriksson P, Omdal R, Rhodus NL, Rischmueller M, Rohrer M, Wahren-Herlenius M, Witte T, Alarcón-Riquelme M, Mariette X, Lessard CJ, Harley JB, Ng WF, Rasmussen A, Sivils KL, Scofield RH.

Arthritis Rheumatol. 2017 Nov;69(11):2187-2192. doi: 10.1002/art.40207. Epub 2017 Oct 12.

28.

A Phase III Study Evaluating Continuation, Tapering, and Withdrawal of Certolizumab Pegol After One Year of Therapy in Patients With Early Rheumatoid Arthritis.

Weinblatt ME, Bingham CO 3rd, Burmester GR, Bykerk VP, Furst DE, Mariette X, van der Heijde D, van Vollenhoven R, VanLunen B, Ecoffet C, Cioffi C, Emery P.

Arthritis Rheumatol. 2017 Oct;69(10):1937-1948. doi: 10.1002/art.40196. Epub 2017 Sep 12.

29.

Thresholds for the 28-joint disease activity score (DAS28) using C-reactive protein are lower compared to DAS28 using erythrocyte sedimentation rate in early rheumatoid arthritis.

Kuriya B, Schieir O, Lin D, Xiong J, Pope J, Boire G, Haraoui B, Thorne JC, Tin D, Hitchon C, Jamal S, Keystone E, Bykerk VP; CATCH Investigators.

Clin Exp Rheumatol. 2017 Sep-Oct;35(5):799-803. Epub 2017 Mar 23.

PMID:
28339365
30.

Targeting the RhoA-ROCK pathway to reverse T-cell dysfunction in SLE.

Rozo C, Chinenov Y, Maharaj RK, Gupta S, Leuenberger L, Kirou KA, Bykerk VP, Goodman SM, Salmon JE, Pernis AB.

Ann Rheum Dis. 2017 Apr;76(4):740-747. doi: 10.1136/annrheumdis-2016-209850. Epub 2016 Nov 9.

31.

Pathologically expanded peripheral T helper cell subset drives B cells in rheumatoid arthritis.

Rao DA, Gurish MF, Marshall JL, Slowikowski K, Fonseka CY, Liu Y, Donlin LT, Henderson LA, Wei K, Mizoguchi F, Teslovich NC, Weinblatt ME, Massarotti EM, Coblyn JS, Helfgott SM, Lee YC, Todd DJ, Bykerk VP, Goodman SM, Pernis AB, Ivashkiv LB, Karlson EW, Nigrovic PA, Filer A, Buckley CD, Lederer JA, Raychaudhuri S, Brenner MB.

Nature. 2017 Feb 1;542(7639):110-114. doi: 10.1038/nature20810.

32.

The effect of rheumatoid arthritis-associated autoantibodies on the incidence of cardiovascular events in a large inception cohort of early inflammatory arthritis.

Barra LJ, Pope JE, Hitchon C, Boire G, Schieir O, Lin D, Thorne CJ, Tin D, Keystone EC, Haraoui B, Jamal S, Bykerk VP; CATCH group.

Rheumatology (Oxford). 2017 May 1;56(5):768-776. doi: 10.1093/rheumatology/kew474.

PMID:
28073956
33.

Adherence and Persistence with Methotrexate in Rheumatoid Arthritis: A Systematic Review.

Curtis JR, Bykerk VP, Aassi M, Schiff M.

J Rheumatol. 2016 Nov;43(11):1997-2009. Epub 2016 Oct 1. Review.

34.

Response to: 'Let's stop fooling ourselves. In RA, only ACR/EULAR criteria define remission and equate with absence of disease!' by Boers.

Emery P, Bingham CO 3rd, Burmester GR, Bykerk VP, Furst DE, Mariette X, Heijde Dv, Vollenhoven Rv, Arendt C, Mountian I, Purcaru O, Tatla D, VanLunen B, Weinblatt ME.

Ann Rheum Dis. 2016 Oct;75(10):e69. doi: 10.1136/annrheumdis-2016-210083. Epub 2016 Aug 12. No abstract available.

35.

Treatment preferences of patients with early rheumatoid arthritis: a discrete-choice experiment.

Hazlewood GS, Bombardier C, Tomlinson G, Thorne C, Bykerk VP, Thompson A, Tin D, Marshall DA.

Rheumatology (Oxford). 2016 Nov;55(11):1959-1968. Epub 2016 Jul 31.

PMID:
27477807
36.

Self-reported comorbidity is common in early inflammatory arthritis and associated with poorer function and worse arthritis disease outcomes: results from the Canadian Early Arthritis Cohort.

Hitchon CA, Boire G, Haraoui B, Keystone E, Pope J, Jamal S, Tin D, Thorne C, Bykerk VP; CATCH investigators.

Rheumatology (Oxford). 2016 Oct;55(10):1751-62. doi: 10.1093/rheumatology/kew061. Epub 2016 Jun 21.

PMID:
27330161
37.

Identifying flares in rheumatoid arthritis: reliability and construct validation of the OMERACT RA Flare Core Domain Set.

Bykerk VP, Bingham CO, Choy EH, Lin D, Alten R, Christensen R, Furst DE, Hewlett S, Leong A, March L, Woodworth T, Boire G, Haraoui B, Hitchon C, Jamal S, Keystone EC, Pope J, Tin D, Thorne JC, Bartlett SJ.

RMD Open. 2016 May 26;2(1):e000225. doi: 10.1136/rmdopen-2015-000225. eCollection 2016.

38.

Certolizumab pegol in combination with dose-optimised methotrexate in DMARD-naïve patients with early, active rheumatoid arthritis with poor prognostic factors: 1-year results from C-EARLY, a randomised, double-blind, placebo-controlled phase III study.

Emery P, Bingham CO 3rd, Burmester GR, Bykerk VP, Furst DE, Mariette X, van der Heijde D, van Vollenhoven R, Arendt C, Mountian I, Purcaru O, Tatla D, VanLunen B, Weinblatt ME.

Ann Rheum Dis. 2017 Jan;76(1):96-104. doi: 10.1136/annrheumdis-2015-209057. Epub 2016 May 10.

39.

Klinefelter's syndrome (47,XXY) is in excess among men with Sjögren's syndrome.

Harris VM, Sharma R, Cavett J, Kurien BT, Liu K, Koelsch KA, Rasmussen A, Radfar L, Lewis D, Stone DU, Kaufman CE, Li S, Segal B, Wallace DJ, Weisman MH, Venuturupalli S, Kelly JA, Alarcon-Riquelme ME, Pons-Estel B, Jonsson R, Lu X, Gottenberg JE, Anaya JM, Cunninghame-Graham DS, Huang AJW, Brennan MT, Hughes P, Alevizos I, Miceli-Richard C, Keystone EC, Bykerk VP, Hirschfield G, Xie G, Siminovitch KA, Ng WF, Nordmark G, Bucher SM, Eriksson P, Omdal R, Rhodus NL, Rischmueller M, Rohrer M, Wahren-Herlenius M, Witte T, Mariette X, Lessard CJ, Harley JB, Sivils KL, Scofield RH.

Clin Immunol. 2016 Jul;168:25-29. doi: 10.1016/j.clim.2016.04.002. Epub 2016 Apr 22. Erratum in: Clin Immunol. 2017 Nov 28;:.

40.

Reduction in Serum Uric Acid May Be Related to Methotrexate Efficacy in Early Rheumatoid Arthritis: Data from the Canadian Early Arthritis Cohort (CATCH).

Lee JJ, Bykerk VP, Dresser GK, Boire G, Haraoui B, Hitchon C, Thorne C, Tin D, Jamal S, Keystone EC, Pope JE.

Clin Med Insights Arthritis Musculoskelet Disord. 2016 Apr 4;9:37-43. doi: 10.4137/CMAMD.S38092. eCollection 2016.

41.

Sustained improvements in MRI outcomes with abatacept following the withdrawal of all treatments in patients with early, progressive rheumatoid arthritis.

Peterfy C, Burmester GR, Bykerk VP, Combe BG, DiCarlo JC, Furst DE, Huizinga TW, Wong DA, Conaghan PG, Emery P.

Ann Rheum Dis. 2016 Aug;75(8):1501-5. doi: 10.1136/annrheumdis-2015-208258. Epub 2016 Feb 10.

42.

X Chromosome Dose and Sex Bias in Autoimmune Diseases: Increased Prevalence of 47,XXX in Systemic Lupus Erythematosus and Sjögren's Syndrome.

Liu K, Kurien BT, Zimmerman SL, Kaufman KM, Taft DH, Kottyan LC, Lazaro S, Weaver CA, Ice JA, Adler AJ, Chodosh J, Radfar L, Rasmussen A, Stone DU, Lewis DM, Li S, Koelsch KA, Igoe A, Talsania M, Kumar J, Maier-Moore JS, Harris VM, Gopalakrishnan R, Jonsson R, Lessard JA, Lu X, Gottenberg JE, Anaya JM, Cunninghame-Graham DS, Huang AJW, Brennan MT, Hughes P, Illei GG, Miceli-Richard C, Keystone EC, Bykerk VP, Hirschfield G, Xie G, Ng WF, Nordmark G, Eriksson P, Omdal R, Rhodus NL, Rischmueller M, Rohrer M, Segal BM, Vyse TJ, Wahren-Herlenius M, Witte T, Pons-Estel B, Alarcon-Riquelme ME, Guthridge JM, James JA, Lessard CJ, Kelly JA, Thompson SD, Gaffney PM, Montgomery CG, Edberg JC, Kimberly RP, Alarcón GS, Langefeld CL, Gilkeson GS, Kamen DL, Tsao BP, McCune WJ, Salmon JE, Merrill JT, Weisman MH, Wallace DJ, Utset TO, Bottinger EP, Amos CI, Siminovitch KA, Mariette X, Sivils KL, Harley JB, Scofield RH.

Arthritis Rheumatol. 2016 May;68(5):1290-1300. doi: 10.1002/art.39560.

43.

Management of perioperative tumour necrosis factor α inhibitors in rheumatoid arthritis patients undergoing arthroplasty: a systematic review and meta-analysis.

Goodman SM, Menon I, Christos PJ, Smethurst R, Bykerk VP.

Rheumatology (Oxford). 2016 Mar;55(3):573-82. doi: 10.1093/rheumatology/kev364. Epub 2015 Oct 7. Review.

44.

Missing Anticitrullinated Protein Antibody Does Not Affect Short-term Outcomes in Early Inflammatory Arthritis: From the Canadian Early Arthritis Cohort.

Shu J, Bykerk VP, Boire G, Haraoui B, Hitchon C, Thorne JC, Tin D, Keystone EC, Pope JE; CATCH Investigators.

J Rheumatol. 2015 Nov;42(11):2023-8. doi: 10.3899/jrheum.150260. Epub 2015 Sep 1.

PMID:
26329342
45.

Heterogeneous Disease Trajectories Explain Variable Radiographic, Function and Quality of Life Outcomes in the Canadian Early Arthritis Cohort (CATCH).

Barnabe C, Sun Y, Boire G, Hitchon CA, Haraoui B, Thorne JC, Tin D, van der Heijde D, Curtis JR, Jamal S, Pope JE, Keystone EC, Bartlett S, Bykerk VP; CATCH Investigators.

PLoS One. 2015 Aug 24;10(8):e0135327. doi: 10.1371/journal.pone.0135327. eCollection 2015.

46.

Determining the Minimally Important Difference in the Clinical Disease Activity Index for Improvement and Worsening in Early Rheumatoid Arthritis Patients.

Curtis JR, Yang S, Chen L, Pope JE, Keystone EC, Haraoui B, Boire G, Thorne JC, Tin D, Hitchon CA, Bingham CO 3rd, Bykerk VP.

Arthritis Care Res (Hoboken). 2015 Oct;67(10):1345-53. doi: 10.1002/acr.22606.

47.

The comparative effectiveness of oral versus subcutaneous methotrexate for the treatment of early rheumatoid arthritis.

Hazlewood GS, Thorne JC, Pope JE, Lin D, Tin D, Boire G, Haraoui B, Hitchon CA, Keystone EC, Jamal S, Bykerk VP; CATCH Investigators.

Ann Rheum Dis. 2016 Jun;75(6):1003-8. doi: 10.1136/annrheumdis-2014-206504. Epub 2015 May 15.

PMID:
25979945
48.

Erratum to: Comparison of tocilizumab as monotherapy or with add-on disease-modifying antirheumatic drugs in patients with rheumatoid arthritis and inadequate responses to previous treatments: an open-label study close to clinical practice.

Bykerk VP, Östör AJ, Alvaro-Gracia J, Pavelka K, Ivorra JA, Graninger W, Bensen W, Nurmohamed MT, Krause A, Bernasconi C, Aassi M, Sibilia J.

Clin Rheumatol. 2015 Jul;34(7):1321. doi: 10.1007/s10067-015-2932-z. No abstract available.

49.

Feasibility and Domain Validation of Rheumatoid Arthritis (RA) Flare Core Domain Set: Report of the OMERACT 2014 RA Flare Group Plenary.

Bartlett SJ, Bykerk VP, Cooksey R, Choy EH, Alten R, Christensen R, Furst DE, Guillemin F, Halls S, Hewlett S, Leong AL, Lyddiatt A, March L, Montie P, Orbai AM, Pohl C, Voshaar MS, Woodworth TG, Bingham CO 3rd.

J Rheumatol. 2015 Nov;42(11):2185-9. doi: 10.3899/jrheum.141169. Epub 2015 Feb 15. Review.

50.

Comparison of tocilizumab as monotherapy or with add-on disease-modifying antirheumatic drugs in patients with rheumatoid arthritis and inadequate responses to previous treatments: an open-label study close to clinical practice.

Bykerk VP, Östör AJ, Alvaro-Gracia J, Pavelka K, Román Ivorra JA, Graninger W, Bensen W, Nurmohamed MT, Krause A, Bernasconi C, Aassi M, Sibilia J.

Clin Rheumatol. 2015 Mar;34(3):563-71. doi: 10.1007/s10067-014-2857-y. Epub 2015 Jan 22. Erratum in: Clin Rheumatol. 2015 Jul;34(7):1321.

Supplemental Content

Loading ...
Support Center